BJPsych Editorial



Gin S. Malhi, Katherine Adlington, Adam Al-Diwani, Shehzad Ali, Rina Arya, David S. Baldwin, Prathiba Batley, Erica Bell, German Berrios, Allan Beveridge, Mohan Bhat, Dinesh Bhugra, Asit Biswas, Sarah Byford, Colin Campbell, Hilary Cass, Rakesh K. Chadda, Samuel R. Chamberlain, Astrid Chevance, Erika Comasco, John Cookson, Harry Costello, Hugo D. Critchley, Pim Cuijpers, Angharad N. de Cates, Riccardo De Giorgi, Claire de Oliveira, Colin Drummond, Jianfeng Feng, Tamsin Ford, Andrew Forrester, John R. Geddes, Judith R. Harrison, Joseph F. Hayes, Scott Henderson, Cyrus S.H. Ho, Philipp Homan, Neil Horn, Konstantinos Ioannidis, Edgar Jones, Eirini Karyotaki, Kenneth R. Kaufman, Ivan Koychev, Veena Kumari, Marinos Kyriakopoulos, Stephen M. Lawrie, William Lee, Anikó Lovik, Philip McGuire, Kwame McKenzie, Edoardo G. Ostinelli, Femi Oyebode, Sarah Peters, Eva Petkova, Michael R. Phillips, Mariana Pinto da Costa, Thomas J. Reilly, Emmert Roberts, Joanne Rodda, A. John Rush, Rob Saunders, Thomas G. Schulze, Frauke Schultze-Lutter, Sukhwinder S. Shergill, Gurubhaskar Shivakumar, Dan Siskind, G. Mustafa Soomro, Ramya Srinivasan, Athula Sumathipala, Kinga Szymaniak, Eric Tan, Leila Tarokh, Derek Tracy, Stuart Watson, Richard Williams, Jingwei Wu, Allan H. Young, Yaara Zisman-Ilani and Emilio Fernandez-Egea

Summary

Recent changes to US research funding are having far-reaching consequences that imperil the integrity of science and the provision of care to vulnerable populations. Resisting these changes, the *BJPsych Portfolio* reaffirms its commitment to publishing mental science and advancing psychiatric knowledge that improves the mental health of one and all.

This Editorial has come about because of recent restructuring of support and funding for science in the USA.¹ Amongst the many changes afoot, some words and phrases are no longer considered to be acceptable by the US Federal Government.² Reorganising research and academic publishing, based on unscientific parameters, threatens the integrity of these important endeavours worldwide.³ These changes are likely to distort research and scientific knowledge, particularly in psychiatry and mental health, and thereby diminish the quality of care provided to those suffering from mental illness.

The list

In March of this year (2025), *The New York Times* published a list of nearly two hundred words, hereafter referred to as 'the list', that the US Federal Government is attempting to 'purge'.² Scientists and research institutions such as the National Science Foundation have been trying to avoid their use, and many words have already been removed from the websites of government agencies.^{1,3} 'The list is alarmingly extensive',³ and seems to be growing, as is the number of researchers being approached to respond to questions that will be used to make programme funding determinations. Attempts to align research endeavours worldwide with US government interests have been described as 'blatant foreign interference'.⁴

In and of itself this is not new, and each incoming US administration, like other governments, has the prerogative to specify their own priorities; however, the political motivations are perhaps more conspicuous on this occasion with the potential inclusion of words such as, for example, 'female', 'women', 'trans' and 'ethnicity', and the explicit mention of 'Hispanic', 'Native American' and 'indigenous community' – topics and groups of people that have been the subject of political debate in recent years. Alongside these words, there are many others on this list that have

Keywords

Ethics; integrity; publishing; psychiatry; science.

Copyright and usage

© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists.

not necessarily been the topic of political debate, such as, for example, 'status', 'most risk', 'inclusion' and 'exclusion', that will negatively impact research more broadly and impede our ability to deal with major health problems, including future pandemics.

In addition to impacting global public health, of particular concern to us are the restrictions placed on words and phrases that will affect psychiatric research. For example, words such as 'disability', 'vulnerable populations' and 'mental health' have been included in the list, which will severely hamstring, if not paralyse, psychiatric practice and mental health research. Therefore, it is imperative to defend the values that underpin academic scientific enquiry, both in our field and more generally, and to emphasise the 'value' of mental science and the importance of publishing 'what matters'.

The value of publishing

The *BJPsych Portfolio* (the Portfolio) is a family of journals that can trace its origins to 1853. The Portfolio comprises *BJPsych Bulletin*, *Advances, International* and *Open*, and the flagship *British Journal of Psychiatry (BJPsych)* which, prior to its current name (assumed in 1963), was known as the *Journal of Mental Science* (see Fig. 1). The term 'mental science' is apt because it indicates that most psychiatric disorders are disorders of the mind that are defined based on mental experiences. Furthermore, the term 'science' serves as a reminder that examining the mind is a systematic endeavour and one that employs scientific methods. Thus, mental science accurately describes the subject matter of the Portfolio and, although it is not a value in the conventional sense, it also describes what the journals publish – and the way they do so is certainly underpinned by important values.

Key amongst these values is scientific integrity. This means that the journals pursue the truth and publish clinical research that has






Fig. 1 The last issue of this journal to bear the name *The Journal of Mental Science*. The cover of issue no. 457, volume 108, November 1962 shows the journal name transition from *The Journal of Mental Science* to *The British Journal of Psychiatry*. The term 'mental science' was used first in the title of this journal in October 1855. The *Asylum Journal of Mental Science* was the predecessor of *The Journal of Mental Science*, which retained this title from 1858 to 1962. In 1963, the journal adopted its current title *The British Journal of Psychiatry*.

been conducted properly; this ensures that the information they provide is trustworthy and can be relied upon. To achieve this, the journal editorial teams subscribe to the core principles of academic publishing⁵ and use these to set standards across the Portfolio. This is important because demonstrating that research is at the core of psychiatry, and that its practice is based on the integration of clinical experience and scientific evidence, as well as patient and public engagement, is vital to its integrity and status as a medical specialty. To this end the Portfolio journals constantly strive to communicate quality mental science, but this would be difficult if not impossible if the very language that psychiatry relies on, the lexicon of science, can no longer be used.

To illustrate this, we briefly discuss a few examples from across the Portfolio. It is important to note that many similar examples could be found for every word on the list, and conversely it would be very difficult to find a single published article in the Portfolio that would not have been diminished by these directives.

The BJPsych Portfolio

A fundamental issue concerning the study of mental illness is health inequality. The word 'inequality' has been flagged in the list, as has 'health disparity', and yet, as expounded in a recent *BJPsych Bulletin* article, 'health inequalities in psychiatry are well established, with people living in poverty [and especially] those from minoritised groups'.⁶ This article, titled 'How can we overcome health inequalities in psychiatry?' is of critical importance because 'psychiatric patients experience significant differences in life expectancy compared with the general population', both because of their mental illness but also because of poorer physical health, and these issues cannot be addressed if research into this subject matter is not undertaken because of underfunding.

Such inequity is not unique to particular populations, but some populations do face additional challenges, such as those articulated by a Special paper published in BJPsych International, which examines the 'Challenges for setting up psychiatric services in a trauma centre in India'.7 The paper exposes part of the broad interface of psychiatry with all of medicine and surgery. The array of 'psychiatric sequelae [that] may occur following traumatic injury irrespective of whether [this impinges on] the brain' is notable, because it can lead not only to 'depression, anxiety [and] posttraumatic stress disorder', as one would anticipate, but also to 'substance use disorder and attention-deficit hyperactivity disorder'. The disability caused is devastating to the individual and imposes a huge burden at the population level due to the high incidence of traumatic injuries. This is also an area that warrants active research and perhaps, as the authors suggest, the development of a dedicated 'trauma psychiatry unit'; however, it is difficult to envisage how this would come about if trauma research were not possible given that 'trauma' and 'traumatic' are flagged terms.

A broader term that is arguably essential to almost all research is the notion of 'bias', which has to be considered in every experiment and paper that is published. In addition to being a statistical concept, personal bias is also a social, medical and legal phenomenon that must first be acknowledged and then understood before it can be minimised. A paper in *BJPsych Advances* examines 'bias in expert witness practice'⁸ and, having defined bias, the authors outline how this inevitable psychological skew may be best managed. Notably, bias is not limited to medicine or law but is also prevalent in day-to-day interactions and experiences; its permeation of our beliefs and thoughts means that it is critical that we have a deep understanding of this intrinsic influence.

Another term that has been flagged is 'mental health' which, if no longer permitted in research protocols and papers, will clearly impact psychiatry. A paper in BJPsych Open, titled 'Suicide-related internet use of mental health patients: what clinicians know',9 is a good example of the kind of impactful research and clinical knowledge that would be lost if research is curbed by the purging of select words. The authors of the paper interviewed a dozen clinicians and found that, although doctors were aware of suicide-related internet use, in which patients go online 'for reasons relating to ... feelings of suicide', they seldom enquired about this behaviour in their clinical consultations. Interestingly, the use of the internet in this circumstance may be a risk factor but at times it may also be protective. Either way, having knowledge of whether this is occurring is clearly beneficial, and this information can be readily elicited by simply asking the relevant questions. The paper makes this point and suggests further training for clinicians on how to enquire about suicide-related internet use. Given the significance of suicide - a phenomenon that is greater in those with a mental illness but occurs not infrequently in the absence of any psychiatric disorder, this type of research, and the examination of factors that affect mental health, are essential.

430

There are many other examples we can furnish to demonstrate the diversity of the scientific topics subsumed within psychiatry that are pivotal to understanding psychiatric disorders as mental conditions, and that have enduring clinical impact. Functionally, psychiatry can be conceptualised akin to a powerful telescope that draws on light from all aspects of human experience, to focus our gaze on the mind and its neural substrates. To observe the granularity of our lives with fidelity, extraordinarily high resolution is needed and, at the same time, 'light' must be captured from people across all walks of life who are engaged in all manner of activities.

Hence, in the past year alone, *BJPsych* has published on cuttingedge scientific matters such as artificial intelligence and its potential for misinformation, and the emerging role of psychedelics (also known as hallucinogens) in the management of psychiatric disorders, as well as debating the contentious issue of assisted dying. At the same time, the Portfolio as a whole has published on equally important psychosocial aspects of mental health such as disability, racism and gender, all of which speak to the identity of individuals suffering from mental illness. These descriptors, that are also on the list, are extremely important because, like many of the words already mentioned, without them mental science would be suppressed and our clinical practice would be forever diminished, as would the esteem in which we hold our profession and the selfesteem of our patients, whom we are committed to serve.

Gin S. Malhi (D), Academic Department of Psychiatry, Kolling Institute, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Australia; CADE Clinic and Mood-T, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Australia; Department of Psychiatry, University of Oxford, UK; and Oxford Uehiro Centre for Practical Ethics, Faculty of Philosophy, University of Oxford, UK; Katherine Adlington 问 Queen Mary University of London, UK; and East London NHS Foundation Trust, London, UK; Adam Al-Diwani 🔟, Department of Psychiatry, University of Oxford, UK; Shehzad Ali (1), Department of Epidemiology and Biostatistics, Schulich School of Medicine, Western University, London, Canada; Department of Health Sciences University of York, UK; and Institute for Mental Health Policy Research, Centre for Addictions and Mental Health (CAMH), Toronto, Canada; Rina Arya (D), School of the Arts, Faculty of Arts, Cultures and Education, University of Hull, UK; David S. Baldwin 问 Faculty of Medicine, University of Southampton, UK; University Department of Psychiatry and Mental Health, University of Cape Town, South Africa; and Mood Disorders Service, Hampshire and Isle of Wight Healthcare NHS Foundation Trust, Southampton, UK; Prathiba Batley (D), Independent Researcher, UK; Erica Bell (D), Academic Department of Psychiatry, Kolling Institute, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Australia; and CADE Clinic and Mood-T, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Australia: German Berrios 🗊 Robinson College, University of Cambridge, UK; Allan Beveridge (D), Editorial Board, British Journal of Psychiatry, UK; Mohan Bhat iD, Kent and Medway NHS and Social Care Partnership Trust, Gillingham, UK; and Faculty of Old age Psychiatry. Roval College of Psychiatrists, London, UK; Dinesh Bhugra (b, King's College London, UK; Asit Biswas (b, University of Leicester, UK; Sarah Byford (b, King's College London, UK; Colin Campbell . King's College London, UK; and South London and Maudsley NHS Foundation Trust, London, UK; Hilary Cass, Evelina London Children's Healthcare, London, UK; Rakesh K. Chadda 向, Department of Psychiatry, Amrita Institute of Medical Sciences, Faridabad, India: Samuel R. Chamberlain (Department of Psychiatry, University of Southampton, UK; and Hampshire and Isle of Wight Healthcare NHS Foundation Trust, Southampton, UK; Astrid Chevance 🔟 Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAF, Center for Research in Epidemiology and Statistics, Paris, France; and Centre d'Epidémiologie Clinique, AP-HP, Hôpital Hôtel Dieu, Paris, France; Erika Comasco (D), Department of Women's and Children's Health, Uppsala University, Sweden; John Cookson (D) Royal London Hospital, London, UK; Harry Costello (D), Division of Psychiatry, University College London, UK; Hugo D. Critchley (10, Department of Clinical Neuroscience, University of Sussex, UK; and Neurodevelopmental Service, Sussex Partnership NHS Foundation Trust, Worthing, UK; **Pim Cuijpers** (b), Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit Amsterdam, Netherlands; and International Institute for Psychotherapy, Babeş-Bolyai University, Romania; Angharad N. de Cates D, Department of Psychiatry, University of Oxford, UK; and Institute for Mental Health, University of Birmingham, UK; Riccardo De Giorgi Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK; and Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK; Claire de Oliveira (1), Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Canada; and ICES, Toronto, Canada; Colin Drummond (), National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; Jianfeng Feng 🔟 , Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, China; Key Laboratory of Computational Neuroscience and Brain Inspired Intelligence (Fudan University), Ministry of Education, Shanghai, China; School of Data Science, Fudan University, China; Zhangjiang Fudan International Innovation Center, Shanghai, China; and Department of Computer

Science, University of Warwick, UK; Tamsin Ford (D), Department of Psychiatry, University of Cambridge, UK; Andrew Forrester (D), Department of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, UK; and Oxleas NHS Foundation Trust, Dartford, UK; John R. Geddes (), Department of Psychiatry, University of Oxford, UK; Judith R. Harrison (), Translational and Clinical Research Institute, Newcastle University, UK; Joseph F. Hayes (D), Division of Psychiatry, University College London, UK; Scott Henderson (D), Centre for Mental Health Research, The Australian National University, Australia; Cyrus S.H. Ho D., Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Philipp Homan (), Department of Adult Psychiatry and Psychotherapy, University of Zurich, Switzerland; and Neuroscience Center Zurich, University of Zurich and ETH Zurich, Switzerland; Neil Horn 🔟, University of Nairobi, Kenya; Mio University, Kenya; Chiromo Hospital Group, Nairobi, Kenya; and Royal College of Psychiatrists, África; Konstantinos Ioannidis 🔞, Hampshire and Isle of Wight Healthcare NHS Foundation Trust, Southampton, UK; and Faculty of Medicine, Department of Psychiatry, University of Southampton, UK; Edgar Jones (), Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; Eirini Karyotaki (), Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit Amsterdam, Netherlands; Department of Clinical Psychology, University of Amsterdam, Netherlands; and Amsterdam Public Health_Research Institute, Amsterdam, Netherlands; Kenneth R. Kaufman (1), Department of Psychiatry, University of Oxford, UK; Departments of Psychiatry, Neurology and Anesthesiology, Rutgers Robert Wood Johnson Medical School, Rutgers University, USA; and Department of Psychological Medicine, School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; Ivan Koychev D, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK: and Department of Brain Sciences, Imperial College London, UK; Veena Kumari 🔟, Department of Psychology and Centre for Cognitive and Clinical Neuroscience, College of Health, Medicine and Life Sciences, Brunel University of London, UK; Marinos Kyriakopoulos (10), South London and Maudsley NHS Foundation Trust, London, UK; 1st Department of Psychiatry National and Kapodistrian University of Athens Vyronas-Kessariani Community Mental Health Centre and Eginition Hospital, Athens, Greece; and Department of Child and Adolescent Psychiatry, Institute of sychiatry, Psychology and Neuroscience, King's College London, UK; Stephen M. Lawrie (10), Division of Psychiatry, Chancellors Building, University of Edinburgh, UK; William Lee 🔟, Cornwall Partnership NHS Foundation Trust, Bodmin, UK; Anikó Lovik (D), Methodology and Statistics Unit, Institute of Psychology, Leiden University, Netherlands; Phillip McGuire (10), Department of Psychiatry, University of Oxford, UK; NIHR Oxford Health Biomedical Research Centre, Oxford, UK; and Oxford Health NHS Foundation Trust, Oxford, UK; Kwame McKenzie (10), Wellesley Institute, Toronto, Canada; University of Toronto, Canada; and Centre for Addictions and Mental Health, Toronto, Canada; Edoardo G. Ostinelli (D), Department of Psychiatry, University of Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK; and Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, UK; Femi Oyebode D, Institute of Mental Health, School of Psychology, University of Birmingham, UK; Sarah Peters D, Manchester Centre for Health Psychology, University of Manchester, UK; Eva Petkova (D), Department of Population Health, Grossman School of Medicine, New York University, USA; and Department of Child and Adolescent Psychiatry, Grossman School of Medicine, New York University, USA; Michael R. Phillips D. Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, China; Mariana Pinto da Costa (10), Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; Thomas J. Reilly (10), Department of Psychiatry, University of Oxford, UK; Emmert Roberts (10), National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; and South London and Maudsley NHS Foundation Trust, London, UK; Joanne Rodda (D), Kent and Medway NHS and Social Care Partnership Trust, Gillingham, UK; and Kent and Medway Medical School, Canterbury, UK; A. John Rush (D), Duke-National University of Singapore, Singapore; Rob Saunders (D), CORE Data Lab, University College London, UK; Thomas G. Schulze (i), Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Germany; Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, SUNY Upstate Medical University, Syracuse, USA; and Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University, Baltimore, USA; Frauke Schultze-Lutter 🗊 Department of Psychiatry and Psychotherapy, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany; Department of Psychology, Faculty of Psychology, Airlangga University, Surabaya, Indonesia; and University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Switzerland; Sukhwinder S. Shergill (b, kent and Medway Medical School, Canterbury, UK; Gurubhaskar Shivakumar (b, Academic Department of Psychiatry, Kolling Institute, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Australia; CADE Clinic and Mood-T, Royal North Shore Hospital, Northern Sydney Local Health District. St Leonards, Australia; and Adult Mental Health Unit, Hornsby Ku-Ring-Gai Hospital, Northern Sydney Local Health District, Hornsby, Australia; Dan Siskind D Medical School, University of Queensland, Brisbane, Australia; and Addiction and Mental Health Service, Metro South Health, Brisbane, Australia; G. Mustafa Soomro (Hampshire and Isle of Wight Healthcare NHS Foundation Trust, Southampton, UK; Ramya Srinivasan (D, Division of Psychiatry, University College London, UK; Athula Sumathipala (D), Institute for Research and Development in Health and Social Care, Sri Lanka; and Faculty of Medicine & Health Sciences, Keele University, UK; Kinga Szymaniak (i), Academic Department of Psychiatry, Kolling Institute, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Australia; and CADE Clinic and Mood-T, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Australia; Eric Tan (1), Centre for Mental Health and Brain Sciences, Swinburne University of Technology, Melbourne, Australia; Leila Tarokh (D), Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Switzerland; Derek Tracy (D), South London and Maudsley NHS Foundation Trust, London, UK; and Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, UK; Stuart Watson (1), Academic Psychiatry and Regional Affective Disorders Service, Wolfson Research Centre, Newcastle University, UK; Richard Williams (1), The University of South Wales, UK; Jingwei Wu (1), Department of Epidemiology and Biostatistics, College of Public Health, Temple University, Philadelphia, USA; Allan H. Young (1), Division of Psychiatry, Imperial College London, UK; Yaara Zisman-Ilani (1), Department of Social and Behavioral Sciences, College of Public Health, Temple University, Philadelphia, USA; and Department of Clinical, Educational and Health Psychology, Division of Psychology and Language Sciences, University College London, UK; **Emilio Fernandez-Egea** (1), Department of Psychiatry, University of Cambridge, UK; and Cambridge Psychosis Centre, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK

Correspondence: Gin S. Malhi. Email: gin.malhi@sydney.edu.au

First received 3 Apr 2025, accepted 5 Apr 2025, first published online 09 Jun

Data availability

Data availability is not applicable because no new data were created or analysed.

Acknowledgements

The views presented in this manuscript are solely those of the authors and do not reflect the views of any organisation or institution.

Author contributions

G.S.M. drafted the manuscript with input from E.B., K.S., G.S., A.B., A.F., K.R.K., M.K., E.F.-E., D.B., S.R.C., A.C., A.N.d.C., N.H., W.L., M.P.d.C., and A.S. All authors have read and approved the manuscript.

Funding

Research for this article received no specific grant from any funding agency, commercial or not-for-profit sectors.

Declaration of interest

The majority of the authors are members of the editorial board of *The British Journal of Psychiatry* and, in addition, several are editors and members of journal boards across the *BJPsych Portfolio*. None of the authors participated in reviewing this paper. Furthermore, as this paper is a Journal Portfolio statement, it has not undergone standard peer review.

G.S.M. has received grant or research support from the National Health and Medical Research Council, Australian Rotary Health, NSW Health, American Foundation for Suicide Prevention, Ramsay Research and Teaching Fund, Elsevier, AstraZeneca, Janssen-Cilag, Lundbeck, Otsuka and Servier, G.S.M has also been a consultant for AstraZeneca, Janssen-Cilag, Lundbeck, Otsuka and Servier, is the recipient of an investigator-initiated grant from Janssen-Cilag (POET Study), joint grant funding from the University of Sydney and National Taiwan University (Ignition Grant) and grant funding from The North Foundation and is also Editor-in-Chief of *BJPsych*.

K.A. has received research funding from National Institute for Health and Care Research (NIHR).

A.A.D. is funded by a NIHR Clinical Lectureship and Academy of Medical Sciences Starter Grant for Clinical Lecturers (no. SGL027\1016).

D.S.B. declares research funding (University of Southampton) from the Medical Research Council, National Institute for Health Research and Idorsia pharmaceuticals.

E.B. has received joint grant funding from the University of Sydney and National Taiwan
University (Ignition Grant) and grant funding from The North Foundation.
A.B. has received grants and research support from the National Institute of Health

A.B. has received grants and research support from the National Institute of Health Research, UK and is Editor-in-Chief of *BJPsych Advances*.

S.R.C. receives an honorarium from Elsevier for journal editorial work. S.R.C.'s research is funded by the National Health Service (NHS).

A.C. has received grant or research support from Fondation pour la Recherche Médicale, Fondation Bettencourt-Schueller, Fondation de France and Fondation Université Paris Cité. H.D.C. receives grant funding for scientific research from research councils and charities

H.D.C. receives grant funding for scientific research from research councils and charities including the Medical Research Council (UKRI), The Wellcome Trust, Great Britain Sasakawa Foundation and Autonomic Charitable Trust.

A.N.d.C. is currently supported by an NIHR Clinical Lectureship and receives, or has recently received, research support from the NIHR Oxford Health BRC (grant no. NIHR203316), the NIHR Mental Health Translational Research Collaboration/Mental Health Mission and the Guarantors of Brain.

T.F. receives funding from Place2Be, a third-sector organisation that provides mental health interventions and training to UK schools for research methods consultation. She has received funding from NIHR, MRC and Wellcome.

J.R.H. works for Akrivia Health as a clinical advisor and serves as an Expert Reviewer (Medical Devices) for the UK Medicines and Healthcare products Regulatory Agency (MHRA). Neither of these roles relate to this work.

J.F.H. has received grant funding from the Wellcome Trust, United Kingdom Research and Innovation, National Institute for Health and Care Research, Medical Research Council UK, Forte. He has received consultancy fees from Wellcome Trust, juli Inc. and Swiss Re.

P.H. has received grants and honoraria from Novartis, Lundbeck, Mepha, Janssen,

Boehringer Ingelheim, Neurolite and OM Pharma. N.H. supports the Gladys Boss Foundation in Kenya, which advocates for the rights and well-being of underserved and vulnerable populations; and has convened a symposium that received sponsorship from Johnson and Johnson, Intas and SunPharma in Kenya.

K.I. receives a stipend from Elsevier for journal editorial work and receives support from the NIHR Applied Research Collaboration ARC Wessex and is funded through an ARC Wessex Internship Award.

I.K. has received honoraria for advisory board roles from J&J and Novo Nordisk and nonpromotional speaker fees from Eisai, is in receipt of an investigator-initiated grant from Novo Nordisk to explore the effects of a GLP-1 receptor agonist in preclinical dementia and is a medical advisor (stock options and/or retainer fees) to the following health technology companies: Five Lives, Oxford Brain Diagnostics, Leaf AI, Paloma Health and Prima Mente (previously CFDX). V.K. has received grant or research support from the Medical Research Council (UK), Economic and Social Research Council (UK), The British Academy and The Wolfson Foundation and joint grant funding from the European Research Development Fund and Learning JBE Limited and The Bial Foundation.

S.M.L. has received funding from Kynexis and Wellcome for running educational sessions for their staff.

A.L. has received project grants from the Fredrik and Ingrid Thuring Foundation, the Karolinska Institute Research Foundation and FORTE (the Swedish Research Council for Health, Working Life and Welfare).

E.G.O. received research and consultancy fees from Angelini Pharma.

S.P. received grant or research support from Medical Research Council, National Institute of Health Research, Mental Health Research UK and Versus Arthritis.

M.R.P. has received grant or research support from the National Natural Science Foundation of China, the Global Alliance for Chronic Diseases and the National Institute of Mental Health.

M.P.C. is the Culture, Equality, Diversity and Inclusion Champion of the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC). T.J.R. is supported by an MRC Clinical Research Training Fellowship (no. MR/W015943/1).

E.R. has received grant or research support from the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC).

J.R. has received grant or research support from the National Institute for Health Research, Alzheimer's Society and Alzheimer's Research UK.

R.S. receives funding through grants from ESRC, RCPsych, MRC and NIHR. He held an unrelated honorary position with NHS England, with his time compensated through financial support to his employing institution.

S.S.S. has received grant or research support from UK Medical Research Council, Wellcome Trust, UK Engineering and Physical Sciences Research Council, National Institute for Health and Care Research (NIHR), Alzheimer's Research UK and Arts & Humanities Research Council, and has been a consultant for Boehringer Ingelheim; and is the recipient of an investigator-initiated grant from Boehringer Ingelheim and joint grant funding from the Kent and Medway Social Care and NHS Partnership Trust and Kent and Medway Medical School.

A.S. has received grant or research support from The Wellcome Trust (UK), Medical Research Council (UK), National Institute of Health Research (UK), Scientific Foundation Board, Royal College of General Practitioners (UK), The Dunhill Medical Trust (UK), National Health & Medical Research Council Australia and WHO (Colombo) and has received travel grants and sponsorships from Fogarty International Center of the NIH USA.

S.W. received grant funding paid to Newcastle University (UK) from the NIHR.

A.H.Y. is employed by Imperial College London, is an honorary consultant psychiatrist (NHS UK) and Editor of the *Journal of Psychopharmacology*. A.H.Y. has been paid for lectures and is on advisory boards for the following companies in regard to drugs used in affective and related disorders: Flow Neuroscience, Novartis, Roche, Janssen, Takeda, Noema pharma, Compass, Astrazenaca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, Allegan, Bionomics, Sumitomo Dainippon Pharma, Sage, Neurocentrx and Otsuka. A.H.Y. is Alegari, biofordinas, dambolio ballipport Harma, sage, Neurobertura and Osaka. Arth. 18 also Principal Investigator on the following studies: the Restore-Life VNS registry study funded by LivaNova, ESKETINTRD3004: 'An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression', 'The Effects of Psilocybin on Cognitive Function in Healthy Participants', 'The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)', 'A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy' (Janssen), 'An Open- label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants with Major Depressive Disorder (MDD)' (Janssen), 'A Randomized, Double-blind, Multicentre, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and 'A Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients with Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNR' (Janssen). A.H.Y. is also UK Chief Investigator for Compass – COMP006 & COMP007 studies – and Novartis MDD study MIJ821A12201. A.H.Y. has recieved the following grant funding (past and present): NIMH (USA), CIHR (Canada), NARSAD (USA), Stanley Medical Research Institute (USA), MRC (UK), Wellcome Trust (UK), Royal College of Physicians (Edin), BMA (UK), UBC-VGH Foundation (Canada), WEDC (Canada), CCS Depression Research Fund (Canada), MSFHR (Canada), NIHR (UK), Janssen (UK) and FU Horizon 2020

E.F.E. has received consultancy honoraria from Boehringer-Ingelheim (2022), Atheneum (2022) and Rovi (2022–24), speaker fees from Adamed (2022–24), Otsuka (2023) and Viatris (2024) and training and editorial honoraria from the Spanish Society of Psychiatry and Mental Health 415 (2023–24).

The remaining authors have no conflict of interest to declare.

Transparency declaration

The authors guarantee that this manuscript is an honest, accurate and transparent account.

References

- 1 Johnson CY, Dance S, Achenbach J. Here Are the Words Putting Science in the Crosshairs of Trump's Orders. The Washington Post, 2025 (https://www. washingtonpost.com/science/2025/02/04/national-science-foundation-trumpexecutive-orders-words/).
- 2 Yourish K, Daniel A, Datar S, White I, Gamio L. *These Words Are Disappearing in the New Trump Administration*. The New York Times, 2025 (https://www.nytimes.com/interactive/2025/03/07/us/trump-federa l-agencies-websites-words-dei.html?smid = url-share).

- 3 van Daal M, Milota M, Jongsma KR. Why banning words in medical research is bad news for everyone. Nat Med [Epub ahead of print] 28 Feb 2025. Available from: https://doi.org/10.1038/s41591-025-03596-9.
- 4 Cassidy C. *Trump Administration Accused of 'Blatant Foreign Interference*. The Guardian, 2025 (https://www.theguardian.com/australia-news/2025/ma r/14/australian-university-sector-accuses-trump-administration-of-blatantinterference-in-research).
- 5 COPE DOAJ OASPA WAME. Principles of Transparency and Best Practice in Scholarly Publishing — English. COPE, 2022 (https://publicationethics.org/guida nce/guideline/principles-transparency-and-best-practice-scholarly-publishing).
- 6 Monk-Cunliffe J. How can we overcome health inequalities in psychiatry? BJPsych Bull 2023; 47: 228–30.
- 7 Chawla N, Chadda RK. Challenges for setting up psychiatric services in a trauma centre in India. *BJPsych Int* 2024; **21**: 4–7.
- 8 Eastman N, Rix K. Bias in expert witness practice: sources, routes to expression and how to minimise it. *BJPsych Adv* 2022; 28: 35–45.
- 9 Bojanić L, Kenworthy J, Moon T, Turnbull P, Ibrahim S, Kapur N, et al. Suiciderelated internet use of mental health patients: what clinicians know. *BJPsych Open* 2024; 10: e195.